NCT02289495View on ClinicalTrials.gov

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 18, 2014

Primary Completion Date

June 27, 2015

Study Completion Date

June 27, 2015

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

GSK2838232

GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours

DRUG

Placebo

Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours

DRUG

Ritonavir

Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02289495 - A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects | Biotech Hunter | Biotech Hunter